Clinical Trials Browser

Withdrawn × tislelizumab × Clear all

NCT06804850 2025-11-19

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

Phase 2 Withdrawn

Head and Neck Neoplasms

NCT06586099 2024-09-19

Tislelizumab with Azacitidine in the Treatment of R/R AML

Phase 1/2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05690035 2024-07-09

Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT05644626 2023-11-29

Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants

Phase 1 Withdrawn

Other solid neoplasm

Solid Tumors

NCT05791097 2023-07-24

AdvanTIG-306

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05809895 2023-07-24

AdvanTIG-211

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT05582031 2023-06-07

REFIT-MSS

Phase 2 Withdrawn

GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Anus Neoplasms, Sarcoma, Colorectal Neoplasms, Small Cell Lung Carcinoma